Revusiran
ALN-TTRSC-005
Phase 2 small_molecule completed
Quick answer
Revusiran for Transthyretin (TTR)-Mediated Amyloidosis is a Phase 2 program (small_molecule) at ALNYLAM PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- ALNYLAM PHARMACEUTICALS, INC.
- Indication
- Transthyretin (TTR)-Mediated Amyloidosis
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed